Chronic lymphocytic leukemia.
暂无分享,去创建一个
J. Byrd | T. Hamblin | G. Dewald | N. Kay | D. Jelinek | M. Lucas | Sherif Farag | T. Lin
[1] T. Robak. Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia , 2004, Hematology.
[2] Arthur Weiss,et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.
[3] R. Greil,et al. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr , 2004, European journal of haematology.
[4] H. Döhner,et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) , 2004, Leukemia.
[5] Lisa L. Smith,et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.
[6] J. Rossi,et al. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] N. Schmitz,et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. , 2004, Blood.
[8] S. Schichman,et al. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) have a Markedly Increased Rate of Second Malignancy, which is the Most Common Cause of Death , 2004, Leukemia & lymphoma.
[9] T. Shanafelt,et al. clinical practice for patients with CLL Prognosis at diagnosis : integrating molecular biologic insights into , 2003 .
[10] P. Gregersen,et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. , 2004, Blood.
[11] S. Schwartz,et al. Incidence of leukemia in Asian migrants to the United States and their descendants , 2002, Cancer Causes & Control.
[12] D. Margaritis,et al. Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia. , 2004, The Hematology Journal.
[13] J. Byrd,et al. Chronic lymphocytic leukemia. , 2004, Hematology. American Society of Hematology. Education Program.
[14] H. Kantarjian,et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia , 2003, Cancer.
[15] F. Ajchenbaum‐Cymbalista,et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Catovsky,et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities , 2003, Annals of Hematology.
[17] R. Gartenhaus,et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] S. Schichman,et al. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma † , 2003, American journal of hematology.
[19] J. Byrd,et al. Rituximab in B-cell chronic lymphocytic leukemia. , 2003, Seminars in oncology.
[20] R. Foà,et al. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. , 2003, Cancer research.
[21] W. Siegert,et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Szczepek,et al. A cholesterol-dependent CD20 epitope detected by the FMC7 antibody , 2003, Leukemia.
[23] D. Catovsky,et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. , 2003, Blood.
[24] G. Juliusson,et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. , 2003, Blood.
[25] Adrian Wiestner,et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.
[26] J. Hainsworth,et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Emili Montserrat,et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.
[28] M. Andreeff,et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. , 2003, Blood.
[29] N. Nakamura,et al. Richter syndrome in B‐cell chronic lymphocytic leukemia , 2003, Pathology international.
[30] D. Scheinberg,et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. O'fallon,et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia , 2003, British journal of haematology.
[32] F. Khuri,et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] S. Stilgenbauer,et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. , 2003, Blood.
[34] G. Guida,et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. , 2003, Blood.
[35] J. Byrd,et al. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211 , 2003, Leukemia.
[36] D. Oscier,et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. , 2003, Blood.
[37] J. Byrd,et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). , 2003, Blood.
[38] Lisa L. Smith,et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. , 2003, Cancer research.
[39] Arthur Weiss,et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.
[40] Chen Wang,et al. Differentiation of monoclonal B lymphocytosis of undetermined significance (MLUS) and chronic lymphocytic leukemia (CLL) with weak CD5 expression from CD5(-) CLL. , 2002, Leukemia research.
[41] E. Giné,et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia , 2002, British journal of haematology.
[42] C. Peschel,et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. , 2002, Blood.
[43] C. Croce,et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[44] R. Bram,et al. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. , 2002, Blood.
[45] R. Houlston,et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. , 2002, Blood.
[46] Lois Shepherd,et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] T. Kipps,et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. , 2002, Blood.
[48] A. Pettitt,et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. , 2002, Blood.
[49] Axel Benner,et al. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.
[50] D. Oscier,et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.
[51] H. Döhner,et al. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. , 2002, The New England journal of medicine.
[52] E. Kimby,et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). , 2002, Blood.
[53] Michael J. Green,et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. , 2002, Blood.
[54] J. Roliński,et al. T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia--the three-color flow cytometry analysis. , 2002, Leukemia research.
[55] J. Gribben,et al. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. , 2002, Blood.
[56] E. Montserrat,et al. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia , 2002, Leukemia.
[57] Xiao-Jie Yan,et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. , 2002, Blood.
[58] J. Byrd,et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.
[59] N. Kay,et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules , 2002, Leukemia.
[60] B. Bauvois,et al. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons , 2002, Leukemia.
[61] F. Appelbaum,et al. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia , 2002, Bone Marrow Transplantation.
[62] J. Byrd,et al. Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma , 2002, Cancer.
[63] M. Chilosi,et al. Chronic B cell malignancies and bone marrow microenvironment. , 2002, Seminars in cancer biology.
[64] A. Rawstron,et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. , 2002, Blood.
[65] Göran Roos,et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. , 2002, Blood.
[66] J. Byrd,et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. , 2002, Blood.
[67] Chen Wang,et al. CD5‐negative phenotype of monoclonal B‐lymphocytosis of undetermined significance (MLUS) , 2002, American journal of hematology.
[68] D. Oscier,et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.
[69] H. Kantarjian,et al. Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.
[70] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[71] L. Bullinger,et al. Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course , 2002, Leukemia.
[72] M. Negrini,et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. , 2002, Haematologica.
[73] T. Stankovic,et al. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD / SCID mice , 2002 .
[74] K. Metze,et al. Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. , 2001, Cytometry.
[75] Y. Tu,et al. Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.
[76] David Botstein,et al. Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.
[77] A. Tefferi,et al. Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia , 2001, British journal of haematology.
[78] J. Byrd,et al. Antibody therapy of acute and chronic leukemias. , 2001, Current Pharmaceutical Biotechnology.
[79] W. Plunkett,et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[80] P. Feugier,et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. , 2001, Blood.
[81] I. Flinn,et al. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[82] J. Góra‐Tybor,et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia , 2001, Leukemia.
[83] M. Andreeff,et al. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia , 2001 .
[84] A. Hartkamp,et al. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. , 2001, European journal of internal medicine.
[85] R. Porcher,et al. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. , 2001, Journal of clinical epidemiology.
[86] K. Do,et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. , 2001, Blood.
[87] V. Morrison. Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia , 2001, Expert review of anticancer therapy.
[88] M Chilosi,et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Blood.
[89] M. Grever,et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] H. Kantarjian,et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] H. Kantarjian,et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] A Domagała,et al. CD52 antigen--a review. , 2001, Medical science monitor : international medical journal of experimental and clinical research.
[93] N. Kay,et al. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B‐CLL patients: impact on clonal B‐cell apoptosis , 2001, British journal of haematology.
[94] T. Robak. Cladribine in the Treatment of Chronic Lymphocytic Leukemia , 2001, Leukemia & lymphoma.
[95] J. Vose,et al. A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's Lymphoma , 2001, Leukemia & lymphoma.
[96] R. Puri,et al. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. , 2001, Critical reviews in immunology.
[97] J. Duijvestijn,et al. Paraneoplastic pemphigus as the initial presentation of chronic lymphocytic leukemia. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[98] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[99] B. Cheson,et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[100] J. Byrd,et al. Campath-1H monoclonal antibody therapy , 2000, Current opinion in oncology.
[101] J. Cawley,et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. , 2000, Blood.
[102] N Tsukada,et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. , 2000, Blood.
[103] M. Błasińska-Morawiec,et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. , 2000, Blood.
[104] M. Grever,et al. Novel therapies for chronic lymphocytic leukemia in the 21st century. , 2000, Seminars in oncology.
[105] M. Goodman,et al. Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. , 2000, Leukemia research.
[106] A. Pembroke,et al. Eosinophilic spongiosis in association with bullous pemphigoid and chronic lymphocytic leukaemia , 2000, The British journal of dermatology.
[107] A. Pileri,et al. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients , 2000, Medical oncology.
[108] B. Barlogie,et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. , 2000, Blood.
[109] M. Grever,et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. , 2000, Blood.
[110] J. Hainsworth,et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. , 2000, Blood.
[111] R. Foà,et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. , 2000, Blood.
[112] T J Hamblin,et al. Immunoglobulin V genes and CD38 expression in CLL. , 2000, Blood.
[113] Apperley,et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP) , 2000, British journal of haematology.
[114] K.,et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B‐cell chronic lymphocytic leukaemia — updated results of the multicentre study of 378 patients , 2000, British journal of haematology.
[115] B. Long,et al. Role of β2 integrins in the prevention of apoptosis induction in chronic lymphocytic leukemia B cells , 2000, Leukemia.
[116] V K Ivanov,et al. A case-control analysis of leukemia in accident emergency workers of Chernobyl. , 2000, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.
[117] N. Kay,et al. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia , 2000, Leukemia.
[118] S. Molica,et al. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B‐cell chronic lymphocytic leukaemia , 1999, British journal of haematology.
[119] T. Kipps,et al. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. , 1999, Blood.
[120] E. Montserrat,et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. , 1999, Blood.
[121] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[122] N. Chiorazzi,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.
[123] H. Döhner,et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. , 1999, Blood.
[124] R. Foà,et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. , 1999, Blood.
[125] S. Aractingi,et al. Subepidermal autoimmune bullous skin diseases associated with B-cell lymphoproliferative disorders. , 1999, Medicine.
[126] D. Catovsky,et al. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. , 1999, Leukemia and Lymphoma.
[127] E. Kimby,et al. Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials , 1999 .
[128] J. Byrd,et al. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study , 1999, British journal of haematology.
[129] S. Johnson,et al. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders , 1999, British journal of haematology.
[130] E. Thiel,et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. , 1999, Blood.
[131] J. Gribben,et al. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia , 1999, Journal of Molecular Medicine.
[132] M. Pfreundschuh,et al. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[133] L. Lagneaux,et al. Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. , 1999, Leukemia & lymphoma.
[134] W. Rowan,et al. Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells , 1998, Immunology.
[135] L. Peterson,et al. Secondary Abnormalities of Chromosome 6q in B‐Cell Chronic Lymphocytic Leukemia: A Sequential Study of Karyotypic Instability in 51 Patients , 1998, American journal of hematology.
[136] N. Ueno,et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] F. Mancini,et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. , 1998, Blood.
[139] K. Maloum,et al. Chlorambucil in Indolent Chronic Lymphocytic Leukemia , 1998 .
[140] J. Byrd,et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[141] C. Croce,et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.
[142] T. Kipps,et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.
[143] Bolam,et al. Association of myelodysplastic changes with purine analogues , 1998, British journal of haematology.
[144] L. Kanz,et al. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. , 1998, Seminars in oncology.
[145] N. Kay,et al. Impairments in immune cell function in B cell chronic lymphocytic leukemia. , 1998, Seminars in oncology.
[146] M. Keating,et al. Chronic lymphocytic leukemia in the young patient. , 1998, Seminars in oncology.
[147] M. Grever,et al. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. , 1998, Seminars in oncology.
[148] D. Easton,et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. , 1998, American journal of human genetics.
[149] K. Maloum,et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. , 1998, The New England journal of medicine.
[150] J. Ritz,et al. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. , 1997, The Journal of clinical investigation.
[151] P. Andersen,et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. , 1997, Leukemia research.
[152] J. Whittaker,et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival , 1997, Leukemia.
[153] V. Lang,et al. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells , 1997, Leukemia.
[154] D. Catovsky,et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). , 1997, American journal of clinical pathology.
[155] D. Catovsky,et al. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12 , 1997, British journal of haematology.
[156] T. Kipps,et al. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia , 1997, Nature Medicine.
[157] Jonathan A. Cooper,et al. p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes* , 1997, The Journal of Biological Chemistry.
[158] F. Morabito,et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B‐cell chronic lymphocytic leukemia , 1997, Cancer.
[159] R. Siebert,et al. Frequent deletions of 6q23–24 in B‐cell non‐Hodgkin's lymphomas detected by fluorescence in situ hybridization , 1997, Genes, chromosomes & cancer.
[160] M. James,et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.
[161] L. Peterson,et al. Isolated 13q14 abnormalities and normal karyotypes are associated with typical lymphocyte morphology in B-cell chronic lymphocytic leukemia. , 1997, American journal of clinical pathology.
[162] S. Tang,et al. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. , 1996, Leukemia & lymphoma.
[163] R. Champlin,et al. Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia , 1996, Annals of Internal Medicine.
[164] E. Serfling,et al. Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. , 1996, Leukemia & lymphoma.
[165] O. Nanni,et al. Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on a priori exposure matrices. , 1996, Occupational and environmental medicine.
[166] M. Hallek,et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. , 1996, Leukemia & lymphoma.
[167] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[168] W. Hiddemann,et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.
[169] L. Peterson,et al. Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. , 1996, American journal of clinical pathology.
[170] G. Juliusson,et al. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[171] E. Montserrat,et al. HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic Leukemia , 1996, Annals of Internal Medicine.
[172] E. Calleja,et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. , 1996, Blood.
[173] L. Foroni,et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro , 1996, British journal of haematology.
[174] D. Catovsky,et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients , 1996, British journal of haematology.
[175] S. Molica,et al. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis. , 1996, Haematologica.
[176] G. Anhalt,et al. Bullous skin diseases. , 1995, Current opinion in immunology.
[177] D. Oscier,et al. Fludarabine‐related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia , 1995, British journal of haematology.
[178] H. Kantarjian,et al. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. , 1995, Blood.
[179] J. Byrd,et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low‐grade lymphoid malignancies: A role for pneumocystis carinii pneumonia prophylaxis , 1995, American journal of hematology.
[180] E Cardis,et al. Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries. , 1995, Radiation research.
[181] A. Rademaker,et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[182] M. Ferguson,et al. Primary Structure of CD52 (*) , 1995, The Journal of Biological Chemistry.
[183] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.
[184] J. Byrd,et al. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[185] R. Zubler,et al. Transfusion‐associated graft‐versus‐host disease in a patient treated with Cladribine (2‐chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis , 1995, British journal of haematology.
[186] D. Catovsky,et al. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. , 1995, Acta haematologica.
[187] M. Andreeff,et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. , 1995, Leukemia.
[188] B. Quesnel,et al. p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .
[189] G. H. Jackson,et al. Transfusion‐associated graft‐versus‐host disease in fludarabine‐treated B‐chronic lymphocytic leukaemia , 1994, British journal of haematology.
[190] C. Geisler,et al. Treatment of hypogammaglobulinemia in chronic lymphocytic leukaemia by low‐dose intravenous gammaglobulin , 1994, European journal of haematology.
[191] A. Delannoy,et al. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia. , 1994, Nouvelle revue francaise d'hematologie.
[192] V. Zagonel,et al. Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non‐Hodgkin's lymphomas. A 9‐year experience at a single institution , 1994, Cancer.
[193] M. Gotic,et al. Successful treatment of refractory pure red cell aplasia secondary to chronic lymphocytic leukaemia with cyclosporine A: correlation between clinical and in vitro effects. , 1994, Nouvelle revue francaise d'hematologie.
[194] T. Chan,et al. The spectrum of chronic lymphoproliferative disorders in Chinese people , 1994, Cancer.
[195] C. Mecucci,et al. Trisomy 12 is uncommon in typical chronic lymphocytic leukaemias , 1994, British journal of haematology.
[196] F. Ries,et al. Intravenous immune globulin in chronic lymphocytic leukaemia. , 1994, Clinical and experimental immunology.
[197] M. Dyer,et al. BCL2 translocations in leukemias of mature B cells. , 1994, Blood.
[198] G. Dighiero,et al. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. , 1994, Immunology today.
[199] S. Molica,et al. Comparison of younger versus older B‐cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases , 1994, European journal of haematology.
[200] B. Andersson,et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[201] E. Estey,et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. , 1994, The New England journal of medicine.
[202] G. Inghirami,et al. Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma). , 1994, Blood.
[203] E. Montserrat,et al. 6 Chronic lymphocytic leukaemia: Prognostic factors and natural history , 1993 .
[204] E. Newcomb,et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .
[205] G. Dighiero. Biology of the neoplastic lymphocyte in B-CLL. , 1993, Bailliere's clinical haematology.
[206] H. Kantarjian,et al. Richter's syndrome: a report on 39 patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[207] E. Estey,et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. , 1993, Blood.
[208] D. Neuberg,et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. , 1993, Blood.
[209] E. Estey,et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. , 1993, Blood.
[210] T. Kipps,et al. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. , 1993, Blood.
[211] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[212] M. Grever,et al. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. , 1993, Leukemia.
[213] L. Baldini,et al. Evidence of clonal progression in a case of Richter syndrome , 1993, Cancer.
[214] H. Kantarjian,et al. Chronic lymphocytic leukemia--correlation of response and survival. , 1993, Leukemia & lymphoma.
[215] H. Kantarjian,et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. , 1993, Leukemia & lymphoma.
[216] E. Estey,et al. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. , 1992, The American journal of medicine.
[217] G. Juliusson,et al. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. , 1992, The New England journal of medicine.
[218] B. Hankey,et al. Second cancers in patients with chronic lymphocytic leukemia. , 1992, Journal of the National Cancer Institute.
[219] E. Anaissie,et al. Listeriosis in Patients with Chronic Lymphocytic Leukemia Who Were Treated with Fludarabine and Prednisone , 1992, Annals of Internal Medicine.
[220] M. Tsan,et al. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia , 1992, American journal of hematology/oncology.
[221] B. Andersson,et al. Serum levels of helper factors (IL-1α, IL-1β and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and β2-microglobulin in patients with B-CLL and benign B lymphocytosis , 1992 .
[222] D. Weisenburger,et al. Richter's syndrome with different immunoglobulin light chain types. Molecular and cytogenetic features indicate a common clonal origin. , 1992, American journal of clinical pathology.
[223] J. Ritz,et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion , 1992 .
[224] E. Montserrat,et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. , 1991, Blood.
[225] S. Molica. Progression and survival studies in early chronic lymphocytic leukemia. , 1991, Blood.
[226] J. Reuben,et al. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia , 1991, The Lancet.
[227] M. Oken,et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[228] A. Gratwohl,et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG. , 1991, Bone marrow transplantation.
[229] S. Tura,et al. Bone marrow transplantation for chronic lymphocytic leukemia. , 1991, Bone marrow transplantation.
[230] H. Kantarjian,et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[231] P. Åman,et al. The leukemic B-cell population of patients with monoclonal lymphocytosis of undetermined significance (MLUS) are functionally distinct from the chronic lymphocytic leukemia (CLL) derived cell population. , 1991, Leukemia research.
[232] D. Oscier,et al. Correlation of chromosome abnormalities with laboratory features and clinical course in B‐cell chronic lymphocytic leukaemia , 1990, British journal of haematology.
[233] S. Knuutila,et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.
[234] B. Grosbois,et al. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. , 1990, Blood.
[235] E. Kimby,et al. Clonal cell surface structures related to differentiation, activation and homing in B‐cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance , 1989, European journal of haematology.
[236] D. W. Jenkins,et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. , 1989, The New England journal of medicine.
[237] B. Barlogie,et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. , 1989, Blood.
[238] H. Gralnick,et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. , 1989, Journal of clinical pathology.
[239] R. Mick,et al. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[240] M. Minden,et al. Immunophenotypic and gene probe analysis of a case of Richter's syndrome. , 1989, American journal of clinical pathology.
[241] H. Mellstedt,et al. Low IL-1 beta production in leukemic cells from progressive B cell chronic leukemia (B-CLL). , 1989, Leukemia research.
[242] E. Kimby,et al. Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS). , 1989, Leukemia research.
[243] P. Giallonardo,et al. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. , 1989, Acta haematologica.
[244] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[245] J. Dick,et al. Engraftment of immune-deficient mice with human hematopoietic stem cells. , 1988, Science.
[246] H. Waldmann,et al. REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H , 1988, The Lancet.
[247] M. Grever,et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group , 1988, American journal of hematology.
[248] A. Randomized. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. , 1988 .
[249] E. Besa. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. , 1988, The American journal of medicine.
[250] E. Montserrat,et al. Serum immunoglobulins in B‐chronic lymphocytic leukemia. Natural history and prognostic significance , 1988, Cancer.
[251] M. Grever,et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. , 1988, Nouvelle revue francaise d'hematologie.
[252] A. Gratwohl,et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: report from the European Cooperative Group for bone marrow transplantation (8 cases). , 1988, Nouvelle revue francaise d'hematologie.
[253] C. Geisler,et al. CHOP versus prednisolone + chlorambucil in chronic lymphocytic leukemia (CLL): preliminary results of a randomized multicenter study. , 1988, Nouvelle revue francaise d'hematologie.
[254] E. Montserrat,et al. Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages. , 1988, Nouvelle revue francaise d'hematologie.
[255] G. Gahrton,et al. Clinical implication of chromosomal aberrations in chronic B-lymphocytic leukaemia cells. , 1988, Nouvelle revue francaise d'hematologie.
[256] P. Rubin,et al. The prognosis and therapy of chronic lymphocytic leukemia under age 50 years. , 1988, Nouvelle revue francaise d'hematologie.
[257] C. Kittas,et al. B-chronic lymphocytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern. , 1988, Nouvelle revue francaise d'hematologie.
[258] M. Linet,et al. Chronic lymphocytic leukemia: epidemiology and etiologic findings. , 1988, Nouvelle revue francaise d'hematologie.
[259] K. Foon,et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. , 1988, The New England journal of medicine.
[260] K. Rai,et al. Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation , 1988, Hematological oncology.
[261] B. Jakšić,et al. High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL--IGCI CLL-01 trial. , 1988, Nouvelle revue francaise d'hematologie.
[262] D. Oscier,et al. Chromosomal abnormalities in B-CLL. , 1988, Nouvelle revue francaise d'hematologie.
[263] J. Kearney,et al. Analysis with antiidiotype antibody of a patient with chronic lymphocytic leukemia and a large cell lymphoma (Richter's syndrome). , 1987, Blood.
[264] J. Alsenz,et al. Autoantibody-mediated acquired deficiency of C1 inhibitor. , 1987, The New England journal of medicine.
[265] G. Rechavi,et al. CHRONIC LYMPHOCYTIC LEUKAEMIA IN TWIN SISTERS: MONOZYGOUS BUT NOT IDENTICAL , 1987, The Lancet.
[266] K. Rai,et al. A review of the prognostic role of cytogenetic, phenotypic, morphologic, and immune function characteristics in chronic lymphocytic leukemia. , 1987, Blood cells.
[267] E. Montserrat,et al. Bone marrow biopsy in chronic lymphocytic leukemia: a review of its prognostic importance. , 1987, Blood cells.
[268] M. Seabright,et al. Chromosome abnormalities involving band 13q14 in hematologic malignancies. , 1987, Cancer genetics and cytogenetics.
[269] M. Tsan,et al. Pure Red‐Cell Aplasia in Patients with Chronic Lymphocytic Leukemia , 1986, Medicine.
[270] D. Oscier,et al. Autoimmunity in chronic lymphocytic leukaemia. , 1986, Journal of clinical pathology.
[271] Ciril Rozman,et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.
[272] M. Grever,et al. Low-dose deoxycoformycin in lymphoid malignancy. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[273] G. Janossy,et al. Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B‐cell chronic lymphocytic leukemia , 1985, Cancer.
[274] J. Pizzuto,et al. [Treatment of chronic lymphocytic leukemia in advanced stages]. , 1985, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
[275] A. Sheffer,et al. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. , 1985, The New England journal of medicine.
[276] D. Longo,et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. , 1985, The American journal of medicine.
[277] E. Montserrat,et al. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. , 1984, Blood.
[278] E. Henderson,et al. Benign monoclonal B cell lymphocytosis--a benign variant of CLL: clinical, immunologic, phenotypic, and cytogenetic studies in 20 patients. , 1984, Blood.
[279] K. Rai,et al. Chronic lymphocytic leukemia. , 1984, The Medical clinics of North America.
[280] E. Henderson,et al. Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia. , 1984, The New England journal of medicine.
[281] M. Chilosi,et al. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. , 1983, Blood.
[282] G. Hale,et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. , 1983, Blood.
[283] H. Checkoway,et al. Lymphocytic leukemia and exposures to benzene and other solvents in the rubber industry. , 1983, Journal of occupational medicine. : official publication of the Industrial Medical Association.
[284] J. Cawley,et al. Glucocorticoid binding and cytolethal responsiveness of hairy-cell and chronic lymphocytic leukaemia. , 2008, Clinical and laboratory haematology.
[285] L. Burmeister,et al. Leukemia and farm practices in Iowa. , 1982, American journal of epidemiology.
[286] Mark J. Thomas,et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.
[287] L. Goodnough,et al. Bullous pemphigoid as a manifestation of chronic lymphocytic leukemia. , 1980, Archives of internal medicine.
[288] Oken Mm,et al. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia. , 1979 .
[289] D. Catovsky,et al. ‘Prolymphocytoid’ Transformation of Chronic Lymphocytic Leukaemia , 1979, British journal of haematology.
[290] M. Liepman,et al. The treatment of chronic lymphocytic leukemia with COP chemotherapy , 1978, Cancer.
[291] C. Huguley. Treatment of chronic lymphocytic leukemia. , 1977, Cancer treatment reviews.
[292] J. Binet,et al. A clinical staging system for chronic lymphocytic leukemia. Prognostic significance , 1977, Cancer.
[293] D C Case,et al. Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.
[294] B. Weinerman,et al. Subsequent neoplasia in chronic lymphocytic leukemia. , 1975, JAMA.
[295] W. Dameshek. Chronic Lymphocytic Leukemia—An Accumulative Disorder of Immunologically Incompetent Lymphocytes. , 1967 .
[296] A. Ciocco,et al. Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time. , 1966, The New England journal of medicine.
[297] D. Galton,et al. The pathogenesis of chronic lymphocytic leukemia. , 1966, Canadian Medical Association journal.
[298] R. Kyle,et al. Large doses of prednisone and prednisolone in the treatment of malignant lymphoproliferative disorders. , 1962, Annals of internal medicine.